The state of North Carolina currently has 46 active clinical trials seeking participants for Arthritis research studies. These trials are conducted in various cities, including Durham, Winston-Salem, Charlotte and Chapel Hill.
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
Recruiting
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: Carteret Medical Group, Morehead City, North Carolina +1 locations
Conditions: Obesity, Overweight, Knee Pain Chronic, Knee Osteoarthritis, Obstructive Sleep Apnea
The Osteoarthritis Prevention Study
Recruiting
The goal of this study is to establish the efficacy of an intervention of dietary weight loss, exercise, and weight-loss maintenance for knee Osteoarthritis (OA) prevention in adult females aged ≥ 50 years with obesity and no or infrequent knee pain. The primary aim is to compare the effects of a dietary weight loss, exercise, and weight-loss maintenance to an attention control group in preventing the development of structural Magnetic Resonance Imaging (MRI) knee OA. Secondary aims will determi... Read More
Gender:
Female
Ages:
50 years and above
Trial Updated:
04/11/2024
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina +1 locations
Conditions: Osteoarthritis, Knee
A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis
Recruiting
This is a parallel group, Phase 2, randomized, double-blind, placebo controlled, 5-arm, international, multicenter, 12-week proof of concept, dose finding study. It is designed to assess efficacy and safety of treatment with SAR441566 for 12 weeks. It will be conducted in male and female adult participants with moderate-to-severe rheumatoid arthritis (RA) not adequately controlled on methotrexate (MTX) and biologic/targeted synthetic disease modifying anti-rheumatic drug (DMARD) naive. Study tr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: Arthritis and Osteoporosis Consultants of the Carolinas Site Number : 8400012, Charlotte, North Carolina +1 locations
Conditions: Rheumatoid Arthritis
A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee
Recruiting
A randomized, double-blind, placebo-controlled, multi-center, phase 3 study to determine the safety and efficacy of TG-C in subjects with Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee, Osteoarthritis Research Society International (OARSI) medial joint space narrowing (JSN) Grade 1 or 2 of the knee joint. TG-C is to be administered by a single intra-articular injection to the damaged joint area via ultrasound guidance. Patients will be followed for 24 months for safety and efficac... Read More
Gender:
All
Ages:
40 years and above
Trial Updated:
04/10/2024
Locations: Brett Gilbert, Durham, North Carolina +1 locations
Conditions: Degenerative Osteoarthritis
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Recruiting
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. PsA that begins before a patient's 16th birthday is called juvenile PsA (jPsA).This study will evaluate how safe risankizumab is for the treatment of psoriatic arthritis and to assess change in disease symptoms. Risankizumab is being studied for the treatment of jPsA and... Read More
Gender:
All
Ages:
Between 5 years and 18 years
Trial Updated:
04/08/2024
Locations: UNC Children's Hospital /ID# 259286, Chapel Hill, North Carolina
Conditions: Juvenile Psoriatic Arthritis
A Study of Baricitinib in Participants With Rheumatoid Arthritis
Recruiting
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2024
Locations: Medication Management, Greensboro, North Carolina +2 locations
Conditions: Rheumatoid Arthritis
A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA
Recruiting
The purpose of the study is to find out if the investigational treatment named QUC398 has beneficial effects on osteoarthritis knee pain and knee cartilage, and if it is safe and well tolerated.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
04/04/2024
Locations: West Clinical Research Private Clinic, Morehead City, North Carolina
Conditions: Osteoarthritis, Knee
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
Recruiting
An open label phase 3 study
Gender:
All
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Sunpharma site no 34, Charlotte, North Carolina +1 locations
Conditions: Psoriatic Arthritis
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
Recruiting
The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-state addenda (DSA) and intervention-specific appendices (ISAs). The ISAs may start independently of other ISAs as interventions become available for clinical testing.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: PharmQuest, Greensboro, North Carolina
Conditions: Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
Recruiting
This is a multicenter Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of tildrakizumab in Subjects with Active Psoriatic Arthritis I (INSPIRE 1)
Gender:
All
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: Sunpharma Site no 52, Charlotte, North Carolina +2 locations
Conditions: Active Psoriatic Arthritis
Platelet-Rich Plasma and the Effects of NSAIDs on Pain and Functional Scores in Knee Osteoarthritis
Recruiting
The primary research purpose is to determine if the use of a drug therapy intervention (each study participant will be randomly assigned to receive one of 3 study medications which will be blinded from everyone, including the study participants, and all research staff (except the principal investigator), combined with a series of 3 injections of Platelet-Rich Plasma (PRP) into an osteoarthritic knee joint, leads to reductions in knee pain, and improvements in physical function. Improvements will... Read More
Gender:
All
Ages:
50 years and above
Trial Updated:
04/01/2024
Locations: QC Kinetix Franchise Group, LLC, 309 South Sharon Amity Rd, Ste 302, Charlotte, North Carolina
Conditions: Osteoarthritis of the Knee, Degenerative Osteoarthritis, Knee Pain Chronic
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis
Recruiting
The purpose of this study is to determine the safety and tolerability of imvotamab in patients with moderate to severe rheumatoid arthritis who have failed prior therapies. Participants will be given imvotamab or placebo through a vein (i.e., intravenously). A placebo is a look-alike substance that contains no active drug
Gender:
All
Ages:
18 years and above
Trial Updated:
03/29/2024
Locations: Accelacare - Salisbury, Salisbury, North Carolina
Conditions: Rheumatoid Arthritis, Arthritis, Rheumatoid, Arthritis